Nano-drug CTS-S-CPT at IR 780 NPs for treating tumors as well as preparation method and application of nano-drug CTS-S-CPT at IR 780 NPs

By designing the CTS-S-CPT@IR780 NPs nano-drug delivery system, the release of camptothecin is controlled by using ROS response, and the solubility, stability and toxic side effects of traditional chemotherapeutic drugs in the treatment of melanoma is solved, achieving an efficient and targeted tumor suppression effect.

CN119679753APending Publication Date: 2025-03-25PEKING UNION MEDICAL COLLEGE HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411860374.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-17
Publication Date
2025-03-25

AI Technical Summary

Technical Problem

Traditional small molecule chemotherapy drugs face problems such as poor solubility and stability in water, rapid clearance in the body, and major toxic side effects when treating melanoma, making it difficult to effectively treat metastatic melanoma.

Method used

A reactive oxygen species (ROS)-responsive camptothecin (CPT) prodrug delivery system CTS-S-CPT@IR780 NPs was designed to form a nanoparticle structure by combining CTS-S-CPT with the sound-sensitive agent IR780, and the production of ROS is used to control the release of CPT and achieve targeted therapy.

Benefits of technology

This nano-drug delivery system can effectively target tumors, and through the synergy of ROS-induced drug release and acoustic dynamic therapy, it significantly inhibits tumor growth and reduces toxic side effects, providing an alternative controlled drug release system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119679753A_ABST
    Figure CN119679753A_ABST
Patent Text Reader

Abstract

The invention discloses a nano-drug CTS-S-CPT-IR 780NPs for treating tumors as well as a preparation method and application of the nano-drug CTS-S-CPT-IR 780NPs, and belongs to the technical field of medicines. Camptothecin and chitosan (CTS) are connected through a long chain, a prodrug CTS-S-CPT in an aqueous solution can be self-assembled and entrapped with a sound-sensitive agent IR 780 to form CTS-S-CPT at IR 780NPs, the covalently-bound prodrug can prevent the drug from leaking in a circulatory system and monitor drug distribution in a body in real time, ROS generated by IR 780 can enable covalent bonds to be broken, the drug is limited to a tumor site, CPT release is controlled, and the drug delivery effect is improved. The toxicity is also generated on tumor cells. Therefore, the CPT-mediated chemotherapy and the IR 780-induced sonodynamic therapy can act together to generate an excellent tumor inhibition effect. This topical, controllable, and on-demand drug release system can provide an alternative option for CPT formulations.
Need to check novelty before this filing date? Find Prior Art